Product Development Pipeline
Product ID
Therapeutic Area/Indications
Discovery Phase
In Vitro Studies
Animal Studies
Clinical Data
Commercialization
Vitynex™ Cream
Wound Healing
VityPatch™ Hydrogel
Wound Healing
CP‑103 Hydrogel
Itching / Dermatitis
CP‑104
(FDA‑approved drug — repositioning)
(FDA‑approved drug — repositioning)
Diabetic Ulcer
Key Milestones:
-
Vitynex™ Cream: Successfully completed clinical data collection and is moving toward commercialization.
-
VityPatch™ Hydrogel: Reached the commercialization stage (market rollout underway).
-
CP-104: Currently in animal studies, showing promising results for wound healing in diabetic ulcers.